Literature DB >> 30338807

A three-microRNA signature predicts clinical outcome in breast cancer patients.

D Cheng1, H He, B Liang.   

Abstract

OBJECTIVE: Breast invasive carcinoma (BRCA) is a complex polygenic disease characterized by molecular and histological heterogeneity. An effort is underway to explore and investigate multiple reliable prognostic markers to improve management of BRCA patients and provide novel therapeutic targets. The aim of the study is to identify the prognostic miRNA signature in BRCA patients. PATIENTS AND METHODS: The miRNA-sequencing data and clinical information of BRCA patients were downloaded from The Cancer Genome Atlas (TCGA) database.
RESULTS: A total of 106 differentially expressed miRNAs were identified between BRCA tissues and matched normal tissues, including 81 up-regulated miRNAs and 25 down-regulated miRNAs. Then, we established a set of three-miRNA signature that was significantly associated with BRCA patients' survival. Using the prognostic three-miRNA signature, we classified the BRCA patients into high-risk and low-risk groups. Multivariate Cox regression demonstrated that the prognostic power of the three-miRNA signature was independent of other clinical variables. Functional enrichment analysis suggested that three prognostic miRNAs may be involved in known BRCA-related KEGG pathways and biological processes.
CONCLUSIONS: We demonstrated that three-miRNA signature could be a potential biomarker for predicting clinical outcomes for BRCA patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30338807     DOI: 10.26355/eurrev_201810_16051

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  3 in total

1.  A cross-cancer metastasis signature in the microRNA-mRNA axis of paired tissue samples.

Authors:  Samuel C Lee; Thomas P Quinn; Alistair Quinn; Thin Nguyen; Svetha Venkatesh
Journal:  Mol Biol Rep       Date:  2019-08-13       Impact factor: 2.316

2.  HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.

Authors:  Carolyn M Klinge; Kellianne M Piell; Christine Schaner Tooley; Eric C Rouchka
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

3.  Identification of RAD54 homolog B as a promising therapeutic target for breast cancer.

Authors:  Jing Feng; Juanjuan Hu; Ying Xia
Journal:  Oncol Lett       Date:  2019-09-12       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.